



A  
CLOSER  
LOOK

# EMGALITY AND MIGRAINE DISEASE

**Emgality**  
(galcanezumab-gnlm) injection

Join us as we examine the mechanism of action for Emgality; its clinical data, dosing, and savings program; and myths that still surround migraine disease.

Emgality is indicated for the preventive treatment of migraine in adults.

## SELECT IMPORTANT SAFETY INFORMATION

### Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.



Join us to learn more about Emgality.

# NOW IS THE TIME FOR PATIENTS WITH MIGRAINE



PROGRAM  
INFORMATION

Wednesday, October 2, 2019

Registration Time:

Presentation Time: 6:00 PM

### Speaker

Chad Allen Whyte, MD

### Location

CopperMill  
421 West Talmadge Road  
Unit 2  
Kearney, Nebraska 68847

### RSVP

AMY SEMPEK-EYRE  
AMY\_SEMPEK-EYRE@LILLY.COM  
402-980-0879  
ANDREA NIZZI  
NIZZI\_ANDREA\_RENAE@LILLY.COM  
402-598-4414

Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

Please see Important Safety Information on the next page, and please see [Full Prescribing Information](#), including [Patient Information](#), for Emgality. See Instructions for Use included with the [pen](#) and [prefilled syringe](#).

**Emgality**  
(galcanezumab-gnlm)  
120 mg injection

## Now Is the Time



With the development of anti-CGRP therapies, this is an exciting era for people with migraine. Join us to learn more about how Emgality works and which patients may be appropriate for this preventive therapy.

## Take a Closer Look

This program will examine:

- The mechanism of action for Emgality
- The results of the phase 3 clinical trial program
- Dosing information
- Safety information
- Savings and support\*
- The role of CGRP and more up-to-date disease knowledge

To be compliant with FDA-mandated transfer of value requirements, all attendees are required to be present for the entire slide presentation. Please see the first page of the invitation for the program registration and start times. Late arrivals are required to review any missed content with the speaker after the conclusion of the program.

This will give you the opportunity to ask a specialist questions in person.

## INDICATIONS

Emgality is a calcitonin gene-related peptide antagonist indicated in adults for the:

- Preventive treatment of migraine
- Treatment of episodic cluster headache

## IMPORTANT SAFETY INFORMATION

### Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

### Warnings and Precautions

#### Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

### Adverse Reactions

The most common adverse reactions (incidence  $\geq 2\%$  and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see [Full Prescribing Information](#), including [Patient Information](#), for Emgality. See Instructions for Use included with the [pen](#) and [prefilled syringe](#).

GZ HCP ISI 04JUN2019

\*Governmental beneficiaries excluded; see [Emgality.com/savings](#) for terms and conditions.

CGRP=calcitonin gene-related peptide. FDA=U.S. Food and Drug Administration.

Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

As a result of enacted state and federal legislation, if you are a prescriber or other licensed healthcare professional with an active license from MA, MN, and/or VT, a Veterans Affairs employee, and/or a state government employee, you may be restricted from accepting industry-provided food/beverage and/or educational item(s). Please consult your state or federal regulations or ethics laws.

This program is intended only for invited healthcare professionals (HCPs) or other appropriate personnel for whom the information that is being presented will be relative to their practice. We regret that spouses or other guests cannot be accommodated.

This program is sponsored by and the speaker is presenting on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Lilly supports and adheres to Kaiser's Standard Operation Policies for Pharmaceutical Manufacturers. Please contact Elise Hatchell, National Accounts, at 510-504-6203, if you have any questions.

Emgality® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

PP-GZ-US-0555 06/2019 ©Lilly USA, LLC 2019. All rights reserved.

**Emgality**  
(galcanezumab-gnlm)  
120 mg injection

*Lilly*

